MEIP News and Press, MEI Pharma Inc. From 02/09/23

MEI Pharma press release ( NASDAQ: MEIP ): Q2 GAAP EPS of $0.08 beats by $0.29 . Revenue of $32.74M (+79.7% Y/Y) beats by $29.4M . For further details see: MEI Pharma GAAP EPS of $0.08 beats by $0.29, revenue of $32.74M beats by $29.4M

-- MEI Begins Third Fiscal Quarter with $124 Million in Cash -- MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended December 31, 2022, and highlighted recent corporate events...

MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on advancing new therapies for cancer, announced today that its annual meeting of stockholders has been adjourned to January 5, 2023, at 9:00 a.m. Pacific Time. The record date for the adjourned annual meeting continues to be Octob...

– Company continuing development efforts on its two early clinical-stage oncology assets: voruciclib and ME-344 – – MEI expects existing cash sufficient to fund through clinical data milestones for voruciclib and ME-344 – MEI Pharma, Inc. (Nasdaq: MEI...

MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a Japan-based global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announ...

- Interim data from Phase II Study of Zandelisib shows 75.4% ORR in Japanese patients with Indolent B-cell NHL - - Publication of results from additional Phase 1 study now available in International Journal of Hematology - Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 415...

MEI Pharma press release ( NASDAQ: MEIP ): Q1 GAAP EPS of -$0.12 beats by $0.04 . Revenue of $8.73M (+12.5% Y/Y) beats by $4.31M . Shares +6.03% AH. For further details see: MEI Pharma GAAP EPS of -$0.12 beats by $0.04, revenue of $8.73M beats by ...

-- MEI Begins Second Fiscal Quarter with $138 Million in Cash -- MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended September 30, 2022, and highlighted recent corpor...

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, tod...

MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Christine A. White, M.D., has decided to retire and thus does not intend to stand for reelection at the Company’s fiscal year 2023 annual meeti...